profit from every $100 of sales.
$0$100
China Pharma Holdings
$0.52-7.47% today
+70.4% in 1 year
1-year low $0.101-year high $1.85
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What China Pharma Holdings sold, what it kept, and what it did with the cash.
Sales went from $8.10 million in 2022 to $4.14 million in 2025, with -$3.19 million of profit last year.
SalesProfit
China Pharma Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| China Pharma Holdings | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads China Pharma Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 8 | 7 | 5 | 4 | |
| -0 | -0 | -2 | -0 | |
| -4 | -3 | -5 | -3 | |
| -1 | 0 | -2 | -2 | |
| -4 | -3 | -5 | -3 | |
| -37.80 | -9.10 | -2.71 | -0.74 | |
| -6.1% | -4.0% | -43.8% | -3.2% | |
| -45.0% | -39.5% | -101.2% | -74.5% | |
| -49.0% | -43.9% | -104.6% | -76.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 18 | 16 | 15 | 31 |
| Cash | 2 | 1 | 1 | 0 |
| Total debt | 9 | 5 | 4 | 4 |
| Total liabilities | 13 | 9 | 7 | 8 |
| 4 | 7 | 8 | 23 | |
| 0 | 0 | 2 | 4 | |
| -21.4% | -17.9% | -31.5% | -9.2% | |
| -92.6% | -41.3% | -61.1% | -14.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -0 | -1 | -0 | 0 | |
| 0 | 0 | 0 | 0 | |
| -1 | -1 | -1 | 0 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | – | – |
Valuation
- –
- –
- –
- 0.5×
- 5.4×
- 2,024.5×
- –
- 0.0%
- -14.3%
- 0.0%
Profitability
- -3.2%
- -74.5%
- -76.9%
- -32.3%
- -8.7%
- -23.2%
- -0.0%
- -7.8%
- -9.5%
- 2,098,506.7%
Growth
- −20.0%
- –
- +101.5%
- –
- −1.8%
Financial health
- –
- 0.10
- 7.9%
- -36.0×
- 0.28
- 0.07
- 0.09
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 28%of 946
Bottom 5%of 871
Bottom 5%of 867
Bottom 41%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.27 | – | – |
| Apr 1, 2026 | -0.04 | – | – |
| Nov 12, 2025 | -0.17 | – | – |
| Aug 14, 2025 | -0.16 | – | – |
| May 21, 2025 | -0.70 | – | – |
| May 14, 2025 | -0.24 | – | – |
| Aug 14, 2024 | -0.09 | – | – |
| May 15, 2024 | -0.07 | – | – |
News
China’s hottest stocks these days have one thing in common: names that sound like sheepMarketWatch · Nov 14, 2026“Very Bad” News for Alibaba: Nvidia’s B300 Servers Now Cost Nearly $3 Million in China.Yahoo Finance · Nov 14, 2026Scott Bessent and Lutnick clash over Nvidia chips and ChinaYahoo Finance · Nov 13, 2026China’s $3.2 Billion AI Pipeline Still Calls for Nvidia Chips Washington RestrictsYahoo Finance · Nov 13, 2026Jensen Huang was a ‘China salesman’ for Nvidia. His exit is weighing on Chinese tech stocks.MarketWatch · Nov 13, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
8No pass
Benjamin Graham
53No pass
Philip Fisher
29No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
21No pass
Terry Smith
7No pass
Questions about China Pharma Holdings
Is China Pharma Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the China Pharma Holdings AI analysis
What does China Pharma Holdings do?
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. It is in Drug Manufacturers - Specialty & Generic.
Does China Pharma Holdings pay a dividend?
No. China Pharma Holdings does not pay a dividend at the moment.
Is China Pharma Holdings stock halal?
Yes. China Pharma Holdings passes our halal screen: its business is permitted and its debt is 17% of its market value, under the 30% limit. How we check
How has China Pharma Holdings stock done over the past year?
Up 70.4% over the past twelve months, to $0.52. It traded between $0.10 and $1.85 and is 72.0% below its high.
Who are China Pharma Holdings's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with China Pharma Holdings's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.